|
|
|
Vol. 13, No. 2, pp. 213-224, January 15, 1999
1 Howard Hughes Medical Institute, 2 Verna and Marrs McLean Department of Biochemistry, 3 Department of Molecular and Human Genetics, 4 Department of Pathology, Baylor College of Medicine, Houston, Texas 77030 USA
| |
Abstract |
|---|
|
|
|---|
Cell-cycle arrest is thought to be required for differentiation of muscle cells. However, the molecules controlling cell-cycle exit and the differentiation step(s) dependent on cell-cycle arrest are poorly understood. Here we show that two Cdk inhibitors, p21CIP1 and p57KIP2, redundantly control differentiation of skeletal muscle and alveoli in the lungs. Mice lacking both p21 and p57 fail to form myotubes, display increased proliferation and apoptotic rates of myoblasts, and display endoreplication in residual myotubes. This point of arrest during muscle development is identical to that of mice lacking the myogenic transcription factor myogenin, indicating a role for cell-cycle exit in myogenin function. Expression of myogenin, p21, and p57 is parallel but independent, and in response to differentiation signals, these proteins are coordinately regulated to trigger both cell-cycle exit and a dependent muscle-specific program of gene expression to initiate myoblast terminal differentiation and muscle formation.
[Key Words: Muscle cell differentation; cell-cycle arrest; myogenin; Cdk inhibitors]
| |
Introduction |
|---|
|
|
|---|
Embryonic development is a complex process that
requires precise spatial and temporal control of cell proliferation
coordinated together with differentiation, morphogenesis, and pattern
formation. Cell proliferation in the embryo is controlled by an
intricate network of signal transduction pathways that integrate growth regulatory signals through regulation of cyclin-dependent kinases (Cdks), a family of enzymes that catalyze events required for cell-cycle transitions. Primary targets for this regulation are the
G1 cyclin/Cdk complexes cyclin
D/Cdk4 and cyclin E/Cdk2, which cooperate
to control the G1
S transition through
phosphorylation and inactivation of the retinoblastoma (Rb) protein.
Among other functions, Rb acts as a transcriptional repressor of
E2F-regulated genes important for cell proliferation (Weinberg 1995
). A
large number of regulatory mechanisms exist to modulate Cdk activity, reflecting the complexity of the signaling pathways involved and the
necessity to precisely control proliferation for the development of an
organism. A particularly versatile mechanism for developmental control
is the inhibition of Cdks by cyclin-dependent kinase inhibitors (CKIs),
of which there are two families: the p16INK4a family,
including p15, p16, p18, and p19; and the
p21CIP1/WAF1 family, including p21, p27, and
p57 (Harper and Elledge 1996
). The p16 family specifically inhibits
Cdk4 and Cdk6, whereas the p21 family inhibits all Cdks involved in
G1/S transition. The roles of these CKIs in
development and in cancer have been revealed through targeted gene
inactivation in mice. Although CKIs show striking tissue-specific
patterns of expression during development, surprisingly only p57
loss has been shown to have a significant role in multiple tissues
during embryonic development, suggesting that the other inhibitors are
either not required or are redundant. Loss of p57 in humans results in
the complex overgrowth and cancer predisposition disease
Beckwith-Wiedemann syndrome (Zhang et al. 1997
).
A variety of studies have indicated that cells must exit the cell cycle
to terminally differentiate. The most revealing of these come from the
analysis of skeletal muscle development. Skeletal muscle development is
controlled by a group of basic helix-loop-helix (bHLH) transcription
factors, including MyoD, Myf5, myogenin, and Mrf4, each of which is
capable of forcing nonmuscle cells to adopt skeletal muscle phenotypes
when expressed ectopically (Olson and Klein 1994
). Analysis of mice
lacking bHLH myogenic factors has revealed a genetic hierarchy in which
MyoD and Myf5 play redundant roles in specifying muscle lineage (the
generation of myoblasts); myogenin directly controls the
differentiation process (the formation of myotubes); and Mrf4 is
thought to be involved in the maturation of myotubes. Early studies
using cultured myoblasts revealed that cell-cycle exit and
differentiation are coupled (Bischoffand Holtzer 1969
; Nadal-Ginard
1978
; Clegg et al. 1987
). Furthermore, MyoD ectopically expressed in
fibroblasts fails to function if these cells are also provided
proliferative stimulation in the form of additional expression of
cyclin D (Rao et al. 1994
; Skapek et al. 1995
), cyclin A, or cyclin E
(Skapek et al. 1996
). Additional connections between cell-cycle exit
and differentiation have been established through analysis of the role
of Rb in skeletal muscle differentiation. These include observations that viral oncogenes capable of inactivating Rb, such as T antigen and
E1A, can interfere with muscle differentiation (Fogel and Defendi 1967
;
Yaffe and Gershon 1967
; Graessmann et al. 1973
; Endo and Nadal-Ginard
1989
; Taylor et al. 1993
; Crescenzi et al. 1995
) and that cells lacking
Rb fail to properly differentiate in vitro (Gu et al. 1993
; Novitch et
al. 1996
). Although Rb-deficient mice display an apparently
normal musculature (Clarke et al. 1992
; Jacks et al. 1992
; Lee et al.
1992
), the early lethality of these mice [before embryonic day 14.5 (E14.5)]has precluded analysis of the role of Rb in secondary
myogenesis when the majority of skeletal muscles are formed (Kelly
1983
). Recently, Zacksenhaus et al. (1996)
reported that
Rb
/
embryos can be rescued to
birth by the low-level expression of an Rb transgene, and
these embryos show skeletal muscle defects. Taken together, this
body of evidence points to an important role for Rb in control of
cell-cycle exit and differentiation in myogenesis.
The Rb protein acts as a switch operated by cell-cycle Cdk machinery to
control cell-cycle entry and exit and is likely to be a critical target
of Cdk regulation relevant to differentiation. However, it is not at
all clear which component of the myogenic regulatory hierarchy requires
Rb for its function. Rb has been shown to interact with MyoD in vitro
(Gu et al. 1993
), although the significance of the interaction is
brought into question by the fact that early targets of MyoD
transcription appear to be fully induced in the absence of Rb (Novitch
et al. 1996
). How Rb is activated to facilitate myogenic
differentiation is currently not known. Although it is likely that Cdk
inactivation is employed, other mechanisms such as increasing the
activity of Rb specific phosphatases are also possible. Furthermore,
assuming that Cdk inactivation is the mechanism, how this is
achieved is not known.
Initial insights into how cell-cycle exit is achieved in vivo came from
the observation that the CKI p21 is highly expressed in muscle and
other terminally differentiating tissues in vivo (Parker et al. 1995
)
and in vitro (Guo et al. 1995
; Halevy et al. 1995
; Parker et al. 1995
).
Furthermore, cells ectopically expressing MyoD can induce p21 when
stimulated to differentiate in vitro suggesting that p21 is a
downstream target of MyoD. However, mice lacking p21 develop normally
and fail to show muscle cell differentiation defects, bringing into
question the role of p21 in muscle development (Deng et al. 1995
). The
absence of a role for p21 in skeletal muscle development could be
explained by redundancy of the cell-cycle control mechanisms. We report
such a redundant mechanism in this study by showing that mice lacking
both p21CIP1 and p57KIP2 display severe defects in
skeletal muscle development (and other tissues including lung); this
indicates that these proteins cooperate as terminal effectors of
signaling pathways that impinge on cell-cycle control and
differentiation. Furthermore, the stage in muscle cell differentiation
at which these double mutants arrest reveals the point at which
cell-cycle exit is required and implicates myogenin function as the
critical step requiring cell-cycle exit.
| |
Results |
|---|
|
|
|---|
Generation of mice lacking both p21CIP1 and p57KIP2
To generate mice lacking p21 and p57, we crossed
p21+/
p57
p/+ females to
p21
/
males. Animals inheriting
the mutant p57 allele from the mother have a p57 null
phenotype because imprinting renders the paternally inherited allele
silent. Consistent with our previous report (Zhang et al. 1997
), there
were no live-born mice lacking either p57 or both p21
and p57 functions (data not shown). However, E16.5 embryos of
all genotypes were detected at Mendelian ratios. A substantial
fraction of p57
m/+ single mutant
(30%) and p21
/
p57
m/+ double mutant (65%) embryos die
in utero due to placental failure (Table 1). Thus,
loss of p21 exacerbates the placental defects observed in
p57
m/+ mutants. The following
phenotypic analysis on p21
/
p57
m/+ double mutants was based on
animals that were not affected by placental failures.
|
p21
/
p57
m/+ double mutants show altered
lung development
Histopathological examination of
p21
/
p57
m/+ mice revealed all of the
phenotypes caused by p57 loss alone (Yan et al. 1997
; Zhang et al. 1997
) and several novel phenotypes in tissues that are apparently unaffected in either of the single mutant animals. Unlike
p21
/
or
p57+/
m animals, the lungs of
p21
/
p57
m/+ animals were clearly defective,
failing to fully differentiate distal air sacs, the ultimate
functioning unit for gas exchange in lung tissue. The mammalian lung is
composed of two types of tissues: an epithelium that lines all the
airways from the trachea to alveoli, and a mesenchymal stroma that
supports the epithelium. Lung development is divided into several
periods. In the pseudoglandular period early during embryogenesis, the
lung resembles an exocrine gland and consists of a complex of branching
bronchial tubes that include the primary, secondary, segmental, and
terminal bronchi and the bronchioles. This is followed by the
canalicular period when respiratory bronchioles are formed. Each
respiratory bronchiole is terminated in two or three thin-walled
dilations termed terminal sacs or primitive alveoli. At E16.5, lungs
from wild-type embryos display substantial formation of primitive
alveoli manifested as open spaces on sections stained with hematoxylin
and eosis (H&E) (Fig. 1A,a). In contrast, lungs from
p21
/
p57+/
m animals are virtually devoid of
open spaces (Fig. 1A,c). Under high magnification, it is evident that
primitive alveoli do not develop in the double mutants (Fig. 1A, cf. d
and e). This defect persists until birth (Fig. 1A, cf. f and g).
Furthermore, there is a decrease in the size of the lumenal space of
the bronchi and bronchioles in the double mutants.
p21+/
p57+/
m lungs exhibit an intermediate
phenotype between the wild-type and the double mutant with some
primitive alveoli but fewer than in the wild type (Fig. 1A, cf. a, b,
and c), indicating that a single p21 gene is insufficient in
the absence of p57.
|
To explore the cause of the lung defect, we examined the expression of both p57 and p21 in the developing lung. p57 is highly expressed in bronchiole epithelium, mirroring that of CC10, a marker for that tissue. p57 is expressed at lower levels in an undefined subset of lung mesenchymal cells and the epithelium lining of the terminal primitive alveoli (Fig. 1B). In contrast, p21 is expressed throughout the lung. Despite high levels of expression of p57 in the bronchiole epithelium, no significant abnormalities were detected in this tissue, and tissue-specific differentiation markers such as CC10 and SP-A, SP-B, and SP-C are expressed normally in double mutants (data not shown). Although the absence of air sac lumenal space gives the appearance of increased cellularity in the mutants, this is not the case. This is due to the fact that the lungs of the double mutant mice are smaller than the wild-type lungs (data not shown); thus, the total number of cells is approximately the same. Furthermore, the overall proliferation rates in the double mutant lung were not elevated as judged by BrdU pulse labeling nor was there an increase in apoptosis (data not shown). Thus, the defects in primitive alveoli formation in the absence of p21 and p57 is likely to result from subtle changes in the differentiation of either the epithelia or the mesenchymal stroma for which additional studies are required to delineate more precisely.
Skeleton defects in p21
/
p57
m/+ double mutants
The only phenotype of p57+/
m
mice that is enhanced by loss of p21 is the skeletal
phenotype. Deletion of p57 alone causes delay in ossification and
sternal fusion defects but no overall abnormality in the shape of the
skeleton (Yan et al. 1997
; Zhang et al. 1997
). However, as shown in
Figure 2, p21
/
p57
m/+ double mutant embryos display a
posture clearly distinct from those of wild-type and
p57
m/+ mutants (Fig.
2A-C). Skeleton staining revealed that double
mutants (Fig. 2E) lack the spinal curvature seen in wild type (Fig. 2D) and p57
m/+ single mutants (data
not shown), which might stem from defects in musculature (see below).
Rib cage shape in double mutant embryos is also abnormal (Fig. 2, cf. D
and E). Bifurcation of ribs was observed in double mutants, usually of
the ninth rib (Fig. 2F), although occasionally the seventh rib is also
affected (Fig. 2J). The femurs of double mutants lack a cartilage
outgrowth seen in either p21 or p57 single mutants or
wild-type littermates (Fig. 2G; data not shown). The double mutants
exhibited sternum fusion defects similar to those seen in p57
single mutants (Zhang et al. 1997
), but the sternum of double mutants
is shorter than that of p57 single mutants (Fig. 2H). The ribs
of double mutants join the sternum at an angle of 90°C (Fig. 2J),
whereas the ribs of wild type or p57 single mutants join at an
angle much less than 90°C (Fig. 2H). Both p21 and
p57 have been found highly expressed in developing ribs (Zhang
et al. 1997
; and data not shown). However, it is difficult to
distinguish autonomous versus nonautonomous roles of these two
inhibitors in ribs, especially considering the fact that similar
defects in the attachment of ribs to sternum are observed in mice
lacking myogenin (Hasty et al. 1993
; Nabeshima et al. 1993
).
|
p21
/
p57
m/+ double mutants exhibit a
profound defect in skeletal muscle
Both p21 and p57 proteins are highly expressed in skeletal muscle,
but neither single mutant animal showed significant muscle cell
differentiation defects (Deng et al. 1995
; Yan et al. 1997
; Zhang et
al. 1997
). However, p21
/
p57
m/+ double mutants exhibit profound
defects in skeletal muscle development. We have found no significant
difference in skeletal muscle development between
p21+/+
p57+/
m and
p21+/
p57+/
m mice (data not shown),
indicating that a single copy of the p21 gene can fully
support skeletal muscle development. As shown by H&E staining of
transverse sections of E18.5 embryos, the intercostal muscle is greatly
reduced in double mutants (Fig. 3, cf. A and B), and
the head muscle is diminished (Fig. 3C,D). In the hind limb, numerous
long myotubes are observed in p21
/
p57+/+ embryos (Fig. 3E), but many fewer
and shorter myotubes are present in double mutants (Fig. 3F). Defects
in the tongue muscle were somewhat less severe, and double mutant
animals exhibit slightly disorganized and less dense muscle mass when
compared to p21
/
p57+/+ animals (Fig. 3, cf. G and H).
|
The diaphragm and body wall muscles of double mutants are also severely diminished as demonstrated by immunofluorescence staining using a monoclonal antibody against myosin heavy chain (MHC). The root of the diaphragm in double mutants is much thinner and poorly stained by the antibody relative to the wild-type control (Fig. 4A,B). MHC staining was diminished in the diaphragm of double mutants when compared to the wild type (Fig. 4C,D). In the body wall, wild-type embryos display three layers of skeletal muscle (Fig. 4E), each of which is diminished in the double mutants (Fig. 4F).
|
It is possible that the skeletal muscle defects observed in double
mutants arise from defects in primary myogenesis by which myoblasts are
specified and migrate out of somites to various places in the embryo to
form skeletal muscles later during secondary myogenesis (Kelley 1983
).
At E13.5, a time when primary myogenesis is well under way, however, we
observed similarly patterned skeletal muscle groups in the double
mutant when compared to a wild-type embryo (Fig. 3I,J). In addition, no
difference in the morphology of somites are detected between double
mutants and wild-type animals at E9.5 (data not shown). Therefore, we
conclude that the skeletal muscle defects in the double mutants are a
result of problems in secondary myogenesis, similar to the defects
observed in mice lacking myogenin (Hasty et al. 1993
; Nabeshima et al.
1993
; Venuti et al. 1995
).
Absence of both p21 and p57 lead to overproliferation, endoreplication, and apoptosis
Given the biochemical function of p21 and p57 as CKIs, proliferation
rates and Cdk2 kinase activities in skeletal muscle from animals with
different genotypes were examined. BrdU pulse labeling in E16.5 embryos
demonstrated a greater than twofold increase in the number of cells
undergoing DNA synthesis in the intercostal muscle region of double
mutants when compared to those of either p21+/
p57+/+ or
p21+/
p57+/
m animals (Fig.
5A-C). We have also noticed incorporation of BrdU in
the nuclei of residual myotubes in double mutants (Fig. 5D, arrows),
indicative of endoreplication. This is never observed in wild type or
single mutants (data not shown). As a result, double mutants frequently
display enlarged and unusually shaped nuclei in the residual myotubes
(Fig. 5, cf. E and F). In agreement with the observed elevation in
proliferation rates in the double mutants, a threefold higher Cdk2
activity toward its physiological substrate Rb protein was detected in
the muscle extracts made from p21
/
p57+/
m relative to
p21+/
p57+/
m animals (Fig. 5I,J), indicating
that p21 and p57 are functioning as CKIs in vivo.
|
The fact that double mutant animals exhibit greatly reduced skeletal muscle mass appears to contradict the fact that they also display increased proliferation. This apparent inconsistency could be explained by an increase in cell death by apoptosis in double mutants. To test that hypothesis, TUNEL assays were performed on transverse sections of E16.5 embryos. Apoptotic cells were readily detected in the double mutants (Fig. 5H) but not in the wild type (Fig. 5G) or single mutants (not shown), explaining the apparent discrepancy. Together, these data indicate that in the absence of both p21 and p57, myoblasts cannot properly withdraw from the cell cycle in response to differentiation signals, leading to overproliferation, endoreplication, and apoptosis.
The block to differentiation in p21
/
p57
m/+ muscle is after the myogenin
expression step
The skeletal muscle and rib phenotypes of
p21
/
p57
m/+
double mutants are nearly identical to those of mice lacking myogenin.
This coincident phenotype could be explained if
p21
/
p57
m/+
animals failed to make myogenin or if myogenin null animals failed to
express p21 and p57. To address this, we examined myogenin expression
in p21
/
p57
m/+ double mutants. In situ
hybridization with a myogenin antisense probe revealed
equivalent expression of myogenin mRNA in all skeletal muscles examined in both wild-type and
p21
/
p57
m/+ double mutant animals (Fig.
6A,B; data not shown). Western blot analysis of hind
limb muscle extracts using a monoclonal antibody against myogenin also
demonstrated similar levels of protein expression and electrophoretic
mobility of myogenin proteins among littermates with various genotypes
(Fig. 6C). To test the functionality of the myogenin protein, we
examined transcription of a gene thought to be downstream of
myogenin, MEF2C, a MADS box-containing
transcription factor involved in myogenesis. MEF2C is expressed at
lower levels in double mutants than that in the wild-type control (Fig.
6D,E). It should be noted that we cannot distinguish between reduced MEF2C expression versus selective loss of MEF2C-expressing cells through apoptosis producing the appearance of reduced MEF2C expression. Nevertheless, these data together demonstrate that the skeletal muscle
phenotypes observed in p21
/
p57
m/+ double mutants are not due to
impaired expression of myogenin, a major skeletal muscle
differentiation transcription factor but may result from an inability
of myogenin or a myogenin-controlled factor to properly function in the
absence of proper cell-cycle exit (see Discussion).
|
p21 and p57 expression are parallel to myogenin expression in the myogenic pathway
The normal expression of myogenin in the
p21
/
p57
m/+ animals indicates that these
two CKIs are not upstream of myogenin in the myogenic
pathway. It is possible that the opposite is true, however
that myogenin actually controls the transcription of both
p21 and p57. To test that possibility, we
investigated the ability of myogenin to induce p21 and p57 expression
in myogenin-expressing 10T1/2 fibroblasts. Unlike
MyoD-programmed 10T1/2 cells induced to differentiate, myogenin was incapable of inducing p21 expression upon serum withdrawal although it could induce its own transcription and cause the formation of myotubes (Fig. 7D). We were unable to detect
induction of p57 in either MyoD- or myogenin-programmed cells in vitro,
suggesting that p57 may be controlled by a novel signal transduction
pathway. To determine the dependency of inhibitor expression on the
presence of myogenin in vivo, we examined p57 and p21
expression in myogenin null animals by in situ hybridization.
As shown in Figure 7, A and B, p57 is expressed at equivalent levels in
myogenin null mice compared to that of wild-type controls.
Taken together with our previous report showing normal p21
expression in myoD/myogenin double mutant
animals (Parker et al. 1995
), we conclude that myogenin is not
required for either p21 or p57 expression. Therefore,
myogenin is neither necessary nor sufficient for the expression of the two inhibitors, resulting in the placement of p21 and
p57 in parallel to myogenin in the myogenic pathway
(see Fig. 7E,F).
|
p21 and p57 are coexpressed in the same cells
The redundancy observed between p21 and p57 can be explained by
redundant activities within each individual myocyte. Alternatively, p21
and p57 can each be required individually in different cell types
representing distinct but redundant myogenic lineages. Such lineages
have been hypothesized to explain the apparent redundancy between MyoD
and Myf5. Furthermore, previous analysis of p57 expression in the
nuclei within myotubes revealed that only half of the nuclei contained
p57 protein, consistent with a two lineage hypothesis (Zhang et al.
1997
). To explore this we sought to determine whether p57 and p21
showed colocalization. For technical reasons we were unable to
visualize p21 protein in myotubes harvested from mice. To circumvent
this, we harvested myoblasts from mice, differentiated them into
myotubes in vitro, and analyzed p21 and p57 protein by indirect
immunofluorescence. Under these circumstance p21 and p57 were found to
be completely colocalized in each nucleus in the myotubes formed (Fig.
7C). This indicates that the redundancy between p21 and p57 is within
an individual cell and not between cells. The difference in the number
of nuclei expressing p57 in vitro versus in vivo is probably due to the
fact that these cells in vitro are synchronized in their
differentiation process. After differentiation, p57 levels drop, and it
is possible that the absence of p57 observed in 50% of nuclei in vivo
reflects nuclei that have already reduced p57 expression.
| |
Discussion |
|---|
|
|
|---|
Proliferation control is vital to a developing organism. CKIs are
good candidates for molecules providing the controls on cellular
proliferation required for embryonic developmental programs because of
their biochemical properties and their patterns of expression. For
example, p21 was found to be highly expressed in a number of terminally
differentiating tissues (Parker et al. 1995
). Surprisingly, however,
mice lacking p16, p21, or p27 display normal embryonic development
(Deng et al. 1995
; Serrano et al. 1996
; Fero et al. 1996
; Kiyokawa et
al. 1996
; Nakayama et al. 1996
), suggesting that other cell-cycle
regulatory mechanisms might exist to compensate for their loss. The
present work reveals such a redundancy and demonstrates that two CKIs,
p21 and p57, cooperate to control proliferation and differentiation in
multiple tissues in mice.
p21 and p57 control differentiation and morphogenesis but not the cell cycle in the lung
The lung develops through interactions between an epithelial tissue that lines airways and a mesenchymal tissue that surrounds the epithelium. It is likely that in the absence of p21 and p57, epithelium-mesenchyme interactions are somehow disrupted in the formation of primitive alveoli. This disruption is stage specific, as development of the bronchial tree is unaffected. Thus far, we have been unable to define more precisely the cell types defective in the lung of mutant animals because p21 and p57 are coexpressed in a number of different cell types and no morphological differences are observed among them.
The lung defects appear to be quite distinct from those observed in
skeletal muscle. First, MyoD and myogenin do not have a role in lung
development, so novel signal transduction pathways are likely to
control p21 and p57 in lung differentiation pathways. Second, in the
absence of p57, muscle can properly differentiate with a single copy of
the p21 gene, whereas the lung shows haploinsufficiency under
these conditions. This is likely to reflect differences in the other
differentiation information present in these cell types. Third, unlike
skeletal muscle, the defects in the formation of primitive alveoli do
not appear to be a result of overproliferation or apoptosis. It is
possible that these two CKIs contribute directly to the differentiation
of either epithelial or mesenchymal cells in a cell-cycle-independent
way. Alternatively, increased Cdk activity caused by the lack of CKIs
might be insufficient to drive the G1/S
transition but sufficient to interfere with the differentiation processes. Analysis of Rb mutants has shown that it is
possible to separate the cell cycle and differentiation functions of
Rb (Sellers et al. 1998
), although whether it is possible to
separate these functions by differential Cdk-dependent phosphorylation is not known. Alternatively, there could exist Cdk-dependent pathways parallel to Rb that are required for differentiation. In support of
this, Skapek et al. (1996)
have shown that additional cyclin D1 could
block myogenesis even in the presence of nonphosphorylatable and
presumably constitutively active Rb. Clearly, however, different tissues can be dependent on the same two regulators in different ways,
underscoring the complex relationship between the cell cycle and development.
p21 and p57 are required for skeletal muscle differentiation
Several studies have suggested a coupling between cell-cycle exit
and differentiation of myoblasts (Bischoff and Holtzer 1969
; Nadal-Ginard 1978
; Clegg et al. 1987
). Furthermore, a large body of
evidence indicates that Rb is necessary for the permanent withdrawal of
skeletal muscle cells from the cell cycle (Gu et al. 1993
; Schneider et
al. 1994
; Novitch et al. 1996
; Mulligan and Jacks 1998
). Because Rb is
a Cdk substrate and is inactivated by Cdk phosphorylation, Cdk
regulation is implicated as a key event in muscle development. How Cdks
are regulated to initiate muscle differentiation has been a difficult
issue to resolve because in vitro differentiation systems utilize
nonphysiological stimuli such as serum deprivation to initiate muscle
cell differentiation. Thus, the mechanistic details of the initial
cell-cycle exit have remained unexplored. This work identifies an
important part of the mechanism through which muscle cells exit the
cell cycle and initiate differentiation in vivo. Mice lacking both p21
and p57 display severe skeletal muscle defects, manifested as a failure to form myotubes, increased proliferation and apoptosis rates of
myoblasts, and endoreplication in the nuclei of residual myotubes. The
skeletal muscle phenotypes are similar to those observed in Rb
/
mice rescued to term by a
Rb transgene expressed at low levels (Zacksenhaus et al. 1996
). This
strongly suggests that the primary role of p21 and p57 is to
down-regulate Cdk activity and maintain Rb in an active
(hypophosphorylated) form. Inactivation of both p21 and p57 leads to
higher Cdk2 kinase activity toward Rb in the skeletal muscle (Fig.
5I,J). Other CKIs have also been implicated in the regulation of pocket
proteins by virtue of phenotypic similarities of mutant mice; p27 and
p57 have been implicated in Rb control in the pituitary and lens,
respectively (Fero et al. 1996
; Kiyokawa et al. 1996
; Nakayama et al.
1996
; Zhang et al. 1997
), and p57 has been implicated in
p107/130 regulation in chondrocyte differentiation (Cobrinik et al. 1996
; Yan et al. 1997
; Zhang et al. 1997
).
p21, p57, and Rb function in muscle development at the myogenin step
To fully differentiate, cells must not only cease proliferation but
also initiate a differentiation program of cell type-specific transcription. An increasing body of evidence suggests that in addition
to its role in cell-cycle exit, hypophosphorylated Rb directly promotes
differentiation by acting as a transcriptional coactivator of
differentiation transcription factors. During adipocyte differentiation, an interaction between Rb and members of the C/EBP family of transcription factors occurs that
potentiates C/EBP DNA binding and transcriptional
activity (Chen et al. 1996
). In terminally differentiating
keratinocytes, Rb interacts with c-Jun and stimulates its
transcriptional activity (Nead et al. 1998
).
In vitro studies coupled with our in vivo genetic studies suggest that
Rb may carry out a similar function in muscle cell differentiation. The
skeletal muscle differentiation pathway is controlled by a group of
bHLH myogenic transcription factors that form a transcriptional
hierarchy in which MyoD and Myf5 are redundant and act upstream of
myogenin, and myogenin is the major differentiation factor (for review,
see Olson and Klein 1994
). Gu et al. (1993)
have shown that Rb
interacts physically with myogenic transcription factors such as MyoD
and myogenin. Furthermore, transcriptional activation of a skeletal
muscle-specific promoter by MyoD requires the presence of a functional
Rb protein (Novitch et al. 1996
). If Rb were required for the function
of a particular muscle transcription factor, one might expect the
phenotype of Rb-deficient animals and
p21
/
p57
m/+ animals to resemble the
phenotype of animals lacking that transcription factor. MyoD mutants
have no phenotype unless combined with Myf5, in which case they are
completely defective in formation of any muscle precursor cell types.
This is clearly different from the Rb
/
and
p21
/
p57
m/+ phenotypes. However, skeletal
muscle defects in p21
/
p57
m/+ double mutants and
Rb
/
mutants rescued by a
hypomorphic Rb transgene bear strong similarity to the defects in
myogenin null mice. This could be due to the failure of a part
of the MyoD/Myf5 program, for example, the failure to
express myogenin. However, myogenin is expressed normally in the double
mutants, suggesting that myogenin, and not MyoD or Myf5, fails to
function in the absence of proper Cdk regulation. Furthermore,
expression of MEF2C, a myogenic transcription factor thought to be
downstream of myogenin (Cserjesi et al. 1994
; Edmondson et al. 1994
;
Molkentin et al. 1995
), is reduced in
p21
/
p57
m/+
animals, consistent with a defect in myogenin activity or an earlier
step. The involvement of myogenin in the Rb-dependent step is supported
by Tedesco et al. (1995)
, who have shown that SV40 T antigen blocks
myogenesis after myogenin has been expressed, and Novitch et al.
(1996)
, who demonstrated that in the absence of Rb, MyoD induces the
expression of both p21 and myogenin, but not later differentiation
markers such as MHC, which depend on the function of myogenin (Hasty et
al. 1993
; Nabeshima et al. 1993
; Venuti et al. 1995
). Whereas myogenin
has been shown to interact physically with Rb in vitro, our studies do
not address whether this connection is direct. The failure to
inactivate Cdks could block the function of myogenin, a
parallel gene required together with myogenin, or a gene
directly downstream of myogenin, and any one of these could physically
require hypophosphorylated Rb.
Muscle differentiation in vivo
what pulls the trigger?
A key issue in muscle development is what triggers the differentiation process. MyoD and Myf5 have been shown to specify the myoblast lineage. Once specified, myoblasts continue to proliferate until they receive a differentiation signal that has not yet been identified. The process initially affected by this signal is not known. However, in vitro cell culture experiments have demonstrated that serum deprivation can trigger differentiation and therefore substitute for the in vivo signal. The dependency on Rb for this process, coupled with the in vivo dependency on p21 and p57, suggests that the relevant function of serum deprivation is cell-cycle arrest through Cdk inactivation. p21 and p57 are essential targets of signal transduction pathways intended to control muscle differentiation in vivo. A critical question is whether p21 and p57 up-regulation in vivo is the trigger for the differentiation cascade or plays a critical downstream coordinating function, or both.
Combining our knowledge of the regulation of myogenic differentiation,
together with the transcriptional regulation of p21 and
p57, sheds some light on these issues. First, both
p21 and p57 are expressed normally in mice deficient
for either MyoD or Myf5 (Parker et al. 1995
; P. Zhang and S. Elledge,
unpubl.), although they may require one of these. Second, MyoD in
10T1/2 cells or C2C12 cells can direct the expression of
p21 but, intriguingly, not p57 (Fig. 7; data not
shown), suggesting that p57 is under the control of a novel
signaling pathway that is not active in the in vitro model systems,
although it is possible that expression of p57 is inactivated
in established cell lines in a manner that does not reflect its true in
vivo regulation. Finally, it is clear that myogenin is neither
necessary nor sufficient for the expression of p21 or p57 and vice
versa, indicating that all three are expressed in parallel. In vitro
model systems such as C2C12 cells show that myogenin expression is low
initially and then highly induced in response to serum deprivation
(Parker et al. 1995
; Andres and Walsh 1996
). If myogenin expression in
vivo is activated after the differentiation trigger is pulled, the fact
that myogenin is fully expressed in the absence of p21 and p57
indicates that these CKIs cannot be the event initially triggering
myocyte differentiation. The major caveat in this analysis is whether
or not myogenin expression in vivo follows the in vitro model or
whether in vivo myogenin is expressed in an inactive form prior to the
triggering event (see below). Alternatively, it is possible that both
p21 and p57 are part of a forward feeding differentiation switch that
once initiated, perhaps by transient cell-cycle exit, maintains the differentiation process, similar to the models put forth for MyoD and
p21 (Halevy et al. 1995
; Parker et al. 1995
).
On the basis of these observations and information from in vitro muscle
differentiation systems, we propose a myogenesis model as depicted in
Figure 7E. MyoD and Myf5 specify cells to adopt the myoblast fate.
Myoblasts then migrate and proliferate. In response to differentiation
signals of unknown origin, expression of myogenin, the driving force in
myoblast differentiation, is activated. At the same time, both p21 and
p57 expression are induced and act to inhibit Cdk activity, causing
G1 arrest and maintaining Rb in its hypophosphorylated and
active form. Rb then works in conjunction with myogenin (or an unknown
factor with a similar function) to activate a program of
muscle-specific gene expression that executes the differentiation
process. A candidate Rb-responsive alternative to myogenin might be
MEF2C, a myogenic transcription factor thought to be downstream of
myogenin. Although MEF2C mutant mice are embryonic lethal and the role
of MEF2C in muscle development has not been assessed, it is likely to
be required for muscle cell differentiation because its
Drosophila homolog, Mef2, is required for muscle formation
(Bour et al. 1995
; Lilly et al. 1995
). Mef2 is the only
Drosophila myogenic homolog required for muscle development.
In this model, CKIs could have additional nonessential roles besides
activation of the myogenin-dependent step, such as enhancing MyoD
function or non-cell-cycle roles in differentiation that are not
indicated in the model. Both p21 and p57 have domains in addition to
the Cdk inhibitory domain that are likely to have other functions,
possibly involved in differentiation.
A second possible model for myogenesis is shown in Figure 7F in which p21 and p57 induction acts as the trigger for muscle differentiation. In this model, after specification, myoblasts express myogenin in an inactive form. The differentiation trigger functions by activating p21 and p57 expression, which inhibits Cdk activity causing G1 arrest and Rb activation. Rb then functions together with myogenin to carry out differentiation. We favor the first model because it is consistent with the results from in vitro muscle differentiation systems. However, the second model makes two testable predictions. If true, myogenin will be expressed in proliferating myoblasts and will be expressed prior to p21 and p57 induction. Furthermore, ectopic activation of p21 or p57 expression in myoblasts should induce muscle differentiation.
Regardless of whether p21 and p57 are the initiating molecules for muscle development, the profound defects observed in p21/p57 double mutant mice demonstrate the pivotal importance of coordination between proliferation and differentiation in development and demonstrate that multiple layers of Cdk regulation have been selected during evolution to ensure this coordination.
| |
Materials and methods |
|---|
|
|
|---|
Genotyping animals
p21-deficient mice were kindly provided by Philip Leder (Harvard Medical School, Boston, MA). We have developed PCR protocols to identify wild-type and disrupted alleles of p21 and p57, using a set of four primers for p21 and three primers for p57. For p21, the sequences are primer 1, TCCTGGTGATGTCCGACCTG; primer 2, TCCGTTTTCGGCCCTGAG; primer 3, GCGAGGATCTCGTCGTGAC, and primer 4, TCATCAATTTATGCAGAC. For p57, the sequences are primer 1, CGTCCACAGGCCGAGTGC; primer 2, GCTGCGGAGGTACACGTCG; and primer 3, GCGAGGATCTCGTCGTGAC. Detailed protocols are available on request.
Gross and histological analysis
Embryos or placentas were fixed in 4% paraffin aldehyde dissolved
in PBS for several hours to overnight at 4°C, depending on the size
of the specimen. Fixed samples were dehydrated using ascending
concentrations of ethanol, cleared in xylene, and embedded in paraffin
wax. Embedded samples were sectioned at 3 µm. For histopathological
evaluation, tissue sections were stained with H&E. Skeleton staining
was performed as described (Ramirez-Solis et al. 1993
)
Immunofluorescence analysis
MHC was detected using a monoclonal antibody (Sigma, clone MY-32)
and visualized with Texas Red-conjugated secondary antibody (Amersham).
p57 was stained as described (Zhang et al. 1997
). For cell
proliferation assays, pregnant mice were injected with BrdU (0.1 µg/gram body weight) 2 hr prior to delivery by
cesarean section, and positive cells identified with an anti-BrdU mAb
(Dako) and visualized with FITC-conjugated secondary antibody
(Amersham). Apoptotic cells were detected with a kit from Trevegene,
and the assay was performed as recommended by the manufacturer.
In situ hybridization
In situ hybridization analysis was performed as described (Parker
et al. 1995
). Sense and antisense probes were generated from linearized
plasmid templates obtained from the following sources: myogenin, Eric
Olson (University of Texas Southwestern Medical Center, Dallas); p21
and p57 (our laboratory); MEF2C, CC10, SP-A, SP-B, and SP-C EST clones
from Genome Systems (St. Louis, MO).
Culture of primary myoblasts
Hind limb muscles dissected from E18.5 embryos were digested with
0.5 ml of dispase (Boehringer Mannheim, Indianapolis, IN.) at 37°C
for 30 min, and tissues were dislodged by repeated pipetting. The
resulting cell suspensions were mixed with DMEM (GIBCO) containing 20%
FBS and appropriate antibiotics, and incubated in 10-cm tissue culture
dishes for 30 min at 37°C to adhere fibroblasts onto the dish. The
supernatants containing myoblasts (and fibroblasts) were plated in
appropriate tissue culture vessels. After a 48-hr recovery period,
myoblasts were induced to differentiate with DMEM containing 2% horse
serum. Myotubes appear by 48 hr after induction. For immunofluorescence
staining, cells were fixed in cold methanol (
20°C).
Protein and mRNA analysis
Hind limb skeletal muscle tissues dissected from E19 embryos were
lysed in NP-40 buffer (Harper et al. 1993
) and cleared by centrifugation. Thirty micrograms of protein was immunoblotted with a
monoclonal anti-myogenin antibody available from Hybridoma Bank
(University of Iowa, Iowa City) using ECL detection (Amersham). GST-myogenin was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). mRNA expression was analyzed by Northern blotting total RNA
isolated from 10T1/2 fibroblasts ectopically expressing
MyoD or myogenin (Parker et al. 1995
). Cdk2 kinase was
immunoprecipitated from muscle extracts using a polyclonal antibody
against Cdk2 (Santa Cruz, CA) and its activity assayed using
Escherichia coli expressed Rb protein (kindly provided by
David Goodrich, University of Texas M.D. Anderson Cancer Center,
Houston) as substrates.
| |
Acknowledgments |
|---|
We thank Philip Leder for p21 mice; Y. Sanchez for help with Cdk2 kinase assays; U. Albrecht and G. Eichele for help and advice on digital photography and F. DeMayo, A. Rawls, E.N. Olson, and A. Lassar for helpful discussions. We thank Developmental Studies Hybridoma Bank for supply of monoclonal antibody against murine myogenin, and Janet Thompson and Laura Depaolis for technical assistance. This work was supported by Department of Defense and National Institutes of Health grants to S.J.E. and J.W.H., and the Baylor SPORE in Prostate Cancer. S.J.E. is an Investigator of the Howard Hughes Medical Institute.
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked `advertisement' in accordance with 18 USC section 1734 solely to indicate this fact.
| |
Footnotes |
|---|
Received October 16, 1998; revised version accepted December 8, 1998.
5 Present address: Division of Basic Sciences, National Jewish Medical and Research Center, Denver, Colorado 80206 USA.
6 Corresponding author.
E-MAIL selledge{at}bcm.tmc.edu; FAX (713) 798-8717.
| |
References |
|---|
|
|
|---|